Literature DB >> 9092

DON, CONV and DONV-III. Pharmacologic and toxicologic studies.

D A Cooney, H N Jayaram, H A Milman, E R Homan, R Pittillo, R I Geran, J Ryan, R J Rosenbluth.   

Abstract

Mesh：

Substances：

Year:  1976        PMID： 9092     DOI： 10.1016/0006-2952(76)90190-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

1.  Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness.

Authors:  A Hofer; D Steverding; A Chabes; R Brun; L Thelander
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation.

Authors:  Shuo Qie; Clarissa Chu; Weihua Li; Chenguang Wang; Nianli Sang
Journal:  J Cell Biochem       Date:  2014-03       Impact factor: 4.429

3.  Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.

Authors:  Jesse Alt; Michelle C Potter; Camilo Rojas; Barbara S Slusher
Journal:  Anal Biochem       Date:  2015-01-10       Impact factor: 3.365

Review 4.  Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation.

Authors:  Ian A Bettencourt; Jonathan D Powell
Journal:  J Immunol       Date:  2017-02-01       Impact factor: 5.422

5.  Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).

Authors:  A Rahman; F P Smith; P T Luc; P V Woolley
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 6.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.